Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine

Am J Dermatopathol. 2008 Apr;30(2):172-3. doi: 10.1097/DAD.0b013e3181660665.

Abstract

Capecitabine, a fluoropyrimidine carbamate with antineoplastic activity, is an oral agent that was developed as a prodrug of 5-fluorouracil and is used in the treatment of metastatic colorectal and breast cancers. Multiple cutaneous adverse effects had been described with the use of this drug, but to our knowledge, specific association with capecitabine and hand-foot syndrome with sclerodactyly-like changes has been described only once. We report a patient with a colon adenocarcinoma who presented with hand-foot syndrome, with sclerodactyly-like changes induced by capecitabine.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Administration, Oral
  • Biopsy, Needle
  • Capecitabine
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Dose-Response Relationship, Drug
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / therapeutic use
  • Follow-Up Studies
  • Hand Dermatoses / chemically induced*
  • Hand Dermatoses / pathology
  • Humans
  • Immunohistochemistry
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Scleroderma, Localized / chemically induced*
  • Scleroderma, Localized / pathology*
  • Severity of Illness Index
  • Sigmoid Neoplasms / drug therapy
  • Sigmoid Neoplasms / pathology
  • Syndrome

Substances

  • Deoxycytidine
  • Capecitabine
  • Fluorouracil